Panacea Biotec Ltd. is a biotechnology company, which is engaged in the business of research, development, manufacture, and marketing of vaccines and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm manufactures a range of paediatric vaccines, including hexavalent vaccine, EasySixTM; pentavalent vaccine, Easyfive- TT and bivalent oral polio vaccine in India and market the same in India, as well as in international markets. The Company’s products include EasySix, Easyfive-TT, Easyfour-TT, EasyFourPol and Bi-OPV. Its pipeline candidates include BPBC, Hepatitis A, Covid-19 VoC mAb, NuVac-23, NuCoVac-11, Td and DengiAll. The firm is in the process of initiating phase III clinical trials for NucoVac-11, DengiAll and Td vaccines. Its operations are spread across different geographies in India. The firm has two manufacturing facilities located in Lalru, Punjab and Baddi, Himachal Pradesh, and two research and development (R&D) centers in Lalru, Punjab and New Delhi.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.